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OBJECTIVE: The Department of Veterans Affairs
(VA) and Department of Defense (DoD) issued a
revised posttraumatic stress disorder (PTSD) Clini-
cal Practice Guideline (CPG) in 2010 with specific
pharmacotherapy recommendations for evidence-
based quality care. The authors examined prescrib-
ing frequencies over an 11-year period prior to the
release of the new guideline to determine gender
differences in pharmacotherapy treatment in veter-
ans with PTSD.
METHOD: National administrative VA data from 1999 to
2009 were used to identify veterans with PTSD using
ICD-9 codes extracted from inpatient discharges and
outpatient clinic visits. Prescribing of antidepressants,
antipsychotics and hypnotics was determined for each
year using prescription drug files.
RESULTS: Women were more likely than men to
receive medication across all classes except prazosin
where men had higher prescribing frequency. The
proportion of women receiving either of the first-line
pharmacotherapy treatments for PTSD, selective se-
rotonin reuptake inhibitors (SSRI) and serotonin-
norepinephrine reuptake inhibitors (SNRI), increased
from 56.4 % in 1999 to 65.7 % in 2009, higher rates
than seen in men (49.2 % to 58.3 %). Atypical
antipsychotic prescriptions increased from 14.6 % to
26.3 % and nonbenzodiazepine hypnotics increased
from 3.8 % to 16.9 % for women, higher frequencies
than seen in men for both medications (OR = 1.31,
1.43 respectively). The most notable gender discrep-
ancy was observed for benzodiazepines where pre-
scriptions decreased for men (36.7 % in 1999 to
29.8 % in 2009) but steadily increased for women
from 33.4 % to 38.3 %.
CONCLUSION: A consistent pattern of increased
prescribing of psychotropic medications among wom-
en with PTSD was seen compared to men. Prescribing
frequency for benzodiazepines showed a marked
gender difference with a steady increase for women
despite guideline recommendations against use and a
decrease for men. Common co-occurring disorders
and sleep symptom management are important fac-
tors of PTSD pharmacotherapy and may contribute to
gender differences seen in prescribing benzodiaze-
pines in women but do not fully explain the apparent
disparity.
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INTRODUCTION
American women represent a disproportionate number of
adults who receive prescriptions for psychotropic medica-
tions, with one in four women receiving such medications
compared to 15 % of men.1 This is particularly true of anti-
anxiety drugs where approximately 11 % of middle-aged
American women (ages 45–64) were receiving benzodiaze-
pines in 2010 compared to a rate that was half that seen in
comparable-aged men (5.7 %).1 One possible contributor to
the higher prescribing rates is the fact that over their
lifetimes women suffer more frequently from psychiatric
disorders than men.2 Another factor may be that women are
also more likely to seek and receive mental health treatment
compared to men.3 It is not clear if elevated psychiatric
medication prescribing among women is solely attributable
to greater diagnostic frequency or whether other reasons
such as gender differences in acceptance and receipt of
mental health treatment may contribute to a significant
degree.
VA is committed to identifying and focusing on women
veterans’ unique health care needs. Women are now the
fastest growing cohort within the veteran community and
represent approximately 16 % of military personnel who
have served in Afghanistan and Iraq.4 The rapid growth of
women veterans makes it particularly important to examine
gender differences in one of the most common diagnoses
among veterans seeking care, PTSD. Unfortunately, there
are virtually no data concerning prescribing differences
across genders in VA, despite the prominent role that
pharmacotherapy plays in the management of PTSD.
Approximately 60 % of privately insured patients with
PTSD receive pharmacotherapy for the disorder,5 while
close to 80 % of veterans receiving care for PTSD in VA are
treated with psychiatric medications.6 In the privately
insured patients, women were 1½ times more likely to
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receive psychotropic medications given a PTSD diagnosis
than men, but we do not know if this is the case for women
veterans treated in the VA.5
Given the prominent role that pharmacotherapy has in the
management of PTSD, we sought to characterize gender
differences in demographic characteristics and psychiatric
comorbidity among veterans with PTSD to examine differ-
ences in prescribing trends among men and women veterans
over an 11-year period (1999–2009) prior to the release of
the new VA guideline and to determine the extent to which
gender-based differences in prescribing frequencies were
explained by demographic and comorbidity variables.
METHODS
Data Source
National administrative VA data were obtained for fiscal
years 1999 through 2009, including outpatient visit data
and inpatient discharge data from the VA Austin Infor-
mation Technology Center (Austin, TX) and pharmacy
data from the VA Pharmacy Benefits Management
Services (Hines, IL). Patient-level data were linked
between these sources using a scrambled patient identi-
fication number. This study was approved by the
University of Iowa Institutional Review Board and the
Iowa City Veterans Administration Research and Devel-
opment Committee.
Patients
Veterans with PTSD were identified using diagnostic codes
extracted from inpatient and outpatient clinic visit data.
Patients were considered to have PTSD during a given year
if they had at least one visit coded for PTSD as either
primary or secondary diagnosis. PTSD was identified using
the International Classification of Diseases, Ninth Revision
(ICD-9) code of 309.81. This case definition has been used
in prior work examining medication use in veterans with
PTSD.6–9 The estimated rate of false-positive cases due to
administrative miscoding is infrequent (<4 %) using this
case definition.10,11
Medication Use
Medication use for each patient was based on having at
least one outpatient prescription fill of any quantity, days’
supply or dosage from within selected therapeutic classes.
Medications were selected based on their classification in
the VA/DOD CPG for PTSD and prior studies of
prescribing practices among veterans with PTSD.6,9,12
These classes included selective serotonin reuptake inhib-
itors (SSRIs), serotonin-norepinephrine reuptake inhibitors
(SNRIs), atypical antipsychotics, benzodiazepines, non-
benzodiazepine hypnotics (included zolpidem, eszopiclone,
zaleplon and ramelteon) and prazosin. Prazosin was
included in the analysis based on its recommendation in
the CPG for targeting symptoms of sleep disturbances and
nightmares.
Demographic Characteristics and Psychiatric
Comorbidity
Demographic and psychiatric comorbidity variables were
determined during 2009. Demographic variables included
gender, age and urban residence. Urban residence was
determined according to Rural–urban Commuting Areas.13
Military service variables included level of VA service-
connected disability rating (monetary benefit paid for injury
or illness incurred during active military service) and
service era, categorized as prior to, during, and post
Vietnam era. Time since first PTSD diagnosis was
categorized as new, 1–2 year history or ≥3 year history of
PTSD in VA. Psychiatric comorbidities were identified by
ICD-9 codes using the same case definition as for PTSD,
which required at least one clinic visit coded as either
primary or secondary diagnosis. The psychiatric comorbid-
ities included in the analysis were depressive disorders,
substance use disorders, traumatic brain injury, panic
disorder, generalized anxiety disorder, obsessive-compul-
sive disorder and social phobia.
Statistical Analysis
Demographic characteristics and psychiatric comorbidity
frequencies were compared between men and women using
a t test for continuous variables and chi-squared test for
categorical variables. Medication prescribing frequencies
were reported separately for men and women spanning the
study time period of 1999–2009. Temporal changes in
gender-based differences in prescribing frequencies were
expressed using odds ratios, where values greater than one
indicated a higher prescribing frequency for women
compared to men.
The influence of demographic characteristics and
psychiatric comorbidity on the likelihood of prescribing
was examined using multiple logistic regression, with
separate analyses conducted for three medication classes
commonly prescribed to veterans with PTSD: SSRI/
SNRIs, atypical antipsychotics and benzodiazepines. The
first step was to report individual multivariable models for
men and women to examine the independent influence of
demographic and comorbidity variables on prescribing and
contrast effects across gender. Comorbidities were selected
for analysis from among DSM-IVAxis I disorders that are
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commonly co-occurring with PTSD or disorders that are
valid indications or relative contraindications to benzodi-
azepine use. The second step was to create four logistic
regression models predicting the likelihood of prescribing:
(1) gender effect only, (2) gender effect adjusted for
demographic variables, (3) gender effect adjusted for
comorbidity variables and (4) gender effect adjusted for
both demographic and comorbidity variables. Changes in
odds ratio for the gender effect across these four models
characterized the extent to which gender-based differences
in prescribing frequencies were explained by demographic
and comorbidity variables. All statistical analyses were
conducted using SAS version 9.3 (Cary, NC).
RESULTS
The number of female veterans being treated for PTSD in
the VA health care system tripled during our time frame,
from 10,484 in 1999 or 6.2 % of the population to 36,978 in
2009, which represents 7.5 % of the treated population.
Compared to men, women were younger, more likely to
have an urban residence, less likely to have a service-
connected disability greater than 50 % and primarily from
the post-Vietnam era (Table 1). Women had higher rates of
all comorbidities examined except for substance use
disorder and traumatic brain injury.
Gender Differences in Prescribing
Women with PTSD were more likely to receive medication
across all classes except prazosin (Table 2). Prescribing
frequency of SSRIs and SNRIs increased for both men and
women. Among women, SSRI/SNRI use increased from
56.4 % in 1999 to 65.7 % in 2009. As prescribing also
increased in men, the gender ratio for SSRI/SNRIs
remained relatively consistent across the 11-year study
period, ranging from 1.34 to 1.57. Gender-based differ-
ences, however, were substantial for benzodiazepines.
Prescriptions for men decreased over time, consistent with
treatment guidelines, but conversely increased over time
among women, from 33.4 % in 1999 to 38.3 % in 2009.
Although benzodiazepine prescriptions were less common
initially among women than men (OR = 0.86), this pattern
reversed such that women were much more likely to receive
a benzodiazepine by 2009 (OR = 1.47). At the beginning of
the study period, atypical antipsychotic prescriptions were
similar between men and women (OR = 1.05). Rates
peaked for both genders in 2005 and decreased thereafter,
with higher use ultimately seen among women in 2009 (OR
= 1.31). Low-dose quetiapine was examined separately and
showed an initial tendency for higher use among women
(OR = 1.88), but by 2009 there was no longer any
meaningful gender gap in its prescribing (OR = 1.04).
Non-benzodiazepine hypnotic prescriptions remained stable
in both men and women until zolpidem was placed on the
national formulary in 2007, resulting in a tripling of its
Table 1. Gender Differences in Patient Characteristics, FY09
Characteristic All Women Men Statistics
N=495,309 N=36,978 N=458,331 χ2 or t; DF; p
Demographics
Age in years, mean (SD) 53.8 (14.6) 43.3 (11.9) 54.7 (14.5) 174; 46,321; <0.0001
Age group, years 29,233; 1; <0.0001
<30 54,343 (11.0 %) 6,535 (17.7 %) 47,808 (10.4 %)
30–39 41,453 (8.4 %) 7,221 (19.5 %) 34,232 (7.5 %)
40–49 52,472 (10.6 %) 10,896 (29.5 %) 41,576 (9.1 %)
50–64 282,451 (57.0 %) 11,409 (30.9 %) 271,042 (59.1 %)
≥65 64,590 (13.0 %) 917 (2.5 %) 63,673 (13.9 %)
Urban residence 359,120 (73.1 %) 29,191 (79.6 %) 329,929 (72.6 %) 862; 1; <0.0001
Service connection >50 % 272,189 (55.0 %) 17,798 (46.5 %) 254,991 (55.6 %) 1,151; 1; <0.0001
Service era 41,275; 1; <0.0001
Pre-Vietnam 32,477 (6.6 %) 408 (1.1 %) 32,069 (7.0 %)
Vietnam 278,299 (56.2 %) 4,625 (12.5 %) 273,674 (59.7 %)
Post-Vietnam 184,533 (37.3 %) 31,945 (86.4 %) 152,588 (33.3 %)
PTSD dx duration in VA 644; 1; <0.0001
New diagnosis 109,159 (22.0 %) 9,674 (26.2 %) 99,485 (21.7 %)
1–2 years 115,282 (23.3 %) 9,331 (25.2 %) 105,951 (23.1 %)
3+ years 270,868 (54.7 %) 17,973 (48.6 %) 252,895 (55.2 %)
Comorbidity
Depressive disorder 240,920 (48.6 %) 24,257 (65.6 %) 216,663 (47.3 %) 4 600; 1; <0.0001
Anxiety disorder, any 39,710 (8.0 %) 5,458 (14.8 %) 34,252 (7.5 %) 2,464; 1; <0.0001
Panic disorder 19,084 (3.9 %) 3,027 (8.2 %) 16,057 (3.5 %) 2025; 1; <0.0001
GAD 19,719 (4.0 %) 2,303 (6.2 %) 17,416 (3.8 %) 528; 1; <0.0001
OCD 3,809 (0.8 %) 676 (1.8 %) 3,133 (0.7 %) 587; 1; <0.0001
Social phobia 1,388 (0.3 %) 161 (0.4 %) 1,227 (0.3 %) 34; 1; <0.0001
Substance use disorder 111,010 (22.4 %) 6,594 (17.8 %) 104,416 (22.8 %) 482; 1; <0.0001
Traumatic brain injury 21,652 (4.4 %) 1,249 (3.4 %) 20,403 (4.5 %) 94; 11; <0.0001
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prescribing rate within 2 years. Again, women were
consistently receiving significantly more of these prescrip-
tions than men in 2009 (OR = 1.43). Prazosin prescribing
was distinct in that prescriptions were consistently lower for
women than men, though prazosin use increased in both
genders. Notably, the gender gap in prazosin use decreased
markedly from an odds ratio of 0.14 in 1999 to 0.75 in
2009.
Independent Predictors of Prescribing
Demographic characteristics and psychiatric comorbidities
were then examined as independent predictors of prescrib-
ing for SSRI/SNRIs, benzodiazepines and atypical anti-
psychotics (Table 3). Age had minimal impact on
prescribing for SSRI/SNRIs in either gender but had
substantial effect on prescribing of benzodiazepines and
atypical antipsychotics. Younger reproductive-age women
had lower rates of receipt of both medications. The atypical
antipsychotics showed an inverted U-shaped pattern of
prescribing where lower rates were seen in younger
veterans, increased in middle age and then showed large
decreases in the oldest age group in both men and women.
An increased percentage of VA service-connected disability
(>50 %) contributed to an increase in prescribing of all
medications for both men and women.
Psychiatric comorbidity had significant impact on pre-
scribing. The likelihood of SSRI/SNRI use was nearly
three-fold higher among patients with co-occurring depres-
sive disorder. Benzodiazepine use was more common for all
anxiety disorder comorbidities, though most dramatically
with panic disorder. Elevated prescribing of atypical
antipsychotics was observed in both men and women with
co-occurring substance use disorder. Traumatic brain injury
was associated with increased prescribing across all
medication classes, except for SSRI/SNRI use in women.
The impact of comorbidity on prescribing was generally
consistent across genders. However, a notable exception
was benzodiazepine use among veterans with comorbid
substance use, which is considered a contraindication
according to guideline recommendations. Among women
veterans, benzodiazepine use was actually higher for
women with co-occurring substance use disorder, whereas
the opposite was true for men.
Gender Effects of Demographic
Characteristics and Comorbidities
The impact of demographic characteristics and psychiatric
comorbidities on gender-based differences in prescribing is
examined in Table 4. Differences in SSRI/SNRI prescribing
were largely attributable to differences in comorbidity
frequency between genders, as shown by the shift in the
gender effect toward a value of one, from an unadjusted
odds ratio of 1.37 to 1.13 after adjustment for psychiatric
comorbidity. In contrast, adjustment for demographic
variables had no effect on the ratio of SSRI/SNRI
prescribing across genders. Competing effects were seen
for benzodiazepine use, where adjustment for demographic
characteristics increased impact of gender, whereas adjust-
ment for comorbidity decreased impact. The net result of
simultaneous adjustment for these effects was a persistence
in gender-based discrepancy in benzodiazepine prescribing
(OR = 1.47) that could not be explained by underlying
difference between genders in demographics or psychiatric
comorbidities. Finally, gender-based differences in atypical
antipsychotic prescribing were primarily attributable to
differences in demographic characteristics, reflected by an
unadjusted odds ratio of 1.31 to 1.08 after the adjustment
for demographics.
DISCUSSION
The primary objective of this work was to examine gender
differences in psychopharmacological prescribing among
veterans with PTSD and determine the extent to which
these differences may be explained by underlying variation
in the frequency of demographic characteristics and
comorbid diagnoses. Women veterans with PTSD are more
likely to have been recently diagnosed, are younger than
men by a decade, have less VA service-connected disability
and are primarily post-Vietnam era. Women were more
likely to have co-occurring depressive and anxiety disor-
ders, whereas men experienced elevated rates of substance
use disorder and traumatic brain injury.
Women veterans were more likely to receive psychotro-
pic medications across all classes except prazosin, which
was more likely in men. The substantial increases in
prescribing of SSRI/SNRIs in women reflect a positive
shift toward evidence-based pharmacological care. This
translates to an additional 18,388 women receiving first-line
recommended medications for the management of PTSD.
When adjusted for psychiatric comorbidities, there are still
higher frequencies of SSRI/SNRIs in women. It is possible
that there are comorbid disorders not accounted for in our
analyses unique to women that contribute to this gender
difference such as premenstrual dysphoric disorder. It is
also possible known sexual side effects cause men to
decline SSRI/SNRIs, and they may represent an under-
treated group. In any case, the increased frequency of SSRI/
SNRIs for women with PTSD should be viewed as a
positive outcome.
We observed comparable guideline-concordant prescrip-
tion patterns with atypical antipsychotics with similar
gender frequencies until a shift occurred in 2003 that saw
an increase for women that stayed elevated compared to
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those for men. When adjusted for demographic character-
istics, there were still elevations in frequency in women that
were not accounted for by different prescribing patterns in
different age groups and for more severe service-connected
disability. It is possible that atypical antipsychotics may be
targeted at insomnia symptoms in women as there is
evidence of gender differences in arousal symptoms.14
However, when we examined low-dose quetiapine sepa-
rately, no gender differences in prescribing were seen. It is
important to note that during this time there were a number
of studies suggesting that atypical antipsychotics were
effective adjunctive treatments for PTSD, and it is possible
again that men were actually undertreated rather than
overuse seen in women.
Prescribing frequencies for benzodiazepines were the
significant exception. As opposed to decreased prescribing
for men, which is guideline-concordance practice, prescrip-
tions steadily increased for women despite recommenda-
tions in the CPG against their use in PTSD because of
safety and efficacy concerns. Chronic use of benzodiaze-
pines can cause cognitive problems, increase the risk of
falls and accidents and have possible detrimental effects on
the recommended psychotherapies for PTSD. With their
abuse and dependence properties, benzodiazepines are
contraindicated in those with comorbid substance use disorder
in patients with PTSD15 as well as contraindicated in those
with TBI.12 Not only did we find increased rates of
prescribing in women, but in women with co-occurring
substance use disorder, rates of benzodiazepine prescriptions
were elevated compared to men, a practice discouraged in the
CPG and one previously noted in a smaller sample.17
Similarly, elevated benzodiazepine prescriptions were seen
in both men and women with TBI, again a contraindicated
practice. The impact of adjustment for demographic character-
istics and psychiatric comorbidities on benzodiazepines was
not straightforward. Some increased frequency of prescrip-
tions for benzodiazepines in women is clearly accounted for
by comorbidities and again may be related to co-occurring
disorders that were not controlled for in our analyses.
However, demographic differences also are influential, and
age is one such factor. Reduced prescribing of benzodiaze-
pines in the youngest reproductive-age group of women when
contrasted to their male counterparts is encouraging. Being
older and having a greater service-connected disability
contributed to elevated benzodiazepine prescribing. It is
possible high rates of distress seen in newly returning
veterans from the wars in Iraq and Afghanistan may be a
reason for an increase in benzodiazepine prescribing.16,17 It is
also possible that clinicians prescribe benzodiazepines to
women for symptoms that are not an indication for their use,
including headache, fatigue, chest pain and vertigo.18
Sleep symptom management clearly plays a prominent
role in PTSD pharmacotherapy. It is possible that increased
prescribing of atypical antipsychotics and benzodiazepines
in women is an attempt to address insomnia symptoms. We
are unable to capture insomnia symptoms associated with
PTSD using administrative data but think that it is
important that this be examined in future work. The
extraordinary 10 % increase in zolpidem use in women
from 2007 to 2009 after the drug became available on
formulary confirms how much sleep difficulties are part of
the clinical presentation of PTSD. It is not clear why this
medication increased so much in women compared to men
nor why prazosin would be the exception and more widely
used in men. The increased use of nonbenzodiazepine
hypnotics does not necessarily reflect a considerably safer
Table 2. Gender Differences in Temporal Prescribing Trends
FY99 FY01 FY03 FY05 FY07 FY09
SSRI/SNRI
Women 56.4 % 62.3 % 68.4 % 67.5 % 66.1 % 65.7 %
Men 49.2 % 53.3 % 58.0 % 58.9 % 58.2 % 58.3 %
OR (95 % CI) 1.34 1.45 1.57 1.45 1.40 1.37
(1.28, 1.39) (1.40, 1.51) (1.51, 1.62) (1.41, 1.49) (1.36, 1.44) (1.34, 1.40)
Benzodiazepines
Women 33.4 % 36.3 % 37.3 % 37.5 % 39.1 % 38.3 %
Men 36.7 % 35.2 % 33.4 % 31.7 % 31.3 % 29.8 %
OR (95 % CI) 0.86 1.05 1.18 1.30 1.41 1.47
(0.83, 0.90) (1.01, 1.09) (1.14, 1.23) (1.26, 1.33) (1.38, 1.45) (1.43, 1.50)
Atypical antipsychotics
Women 14.6 % 21.6 % 27.6 % 29.0 % 26.6 % 26.3 %
Men 14.1 % 20.1 % 25.1 % 25.6 % 22.5 % 21.3 %
OR (95 % CI) 1.05 1.09 1.14 1.19 1.25 1.31
(0.99, 1.11) (1.05, 1.15) (1.10, 1.18) (1.15, 1.22) (1.22, 1.29) (1.28, 1.35)
Zolpidem
Women 3.8 % 5.7 % 5.6 % 5.5 % 6.1 % 16.9 %
Men 3.8 % 4.9 % 4.3 % 3.9 % 4.2 % 12.4 %
OR (95 % CI) 1.02 1.18 1.33 1.44 1.48 1.43
(0.92, 1.13) (1.09, 1.28) (1.24, 1.43) (1.35, 1.53) (1.40, 1.56) (1.39,1.48)
Prazosin
Women 0.2 % 0.7 % 1.9 % 3.5 % 5.0 % 7.1 %
Men 1.5 % 1.6 % 2.6 % 4.8 % 6.4 % 9.3 %
OR (95 % CI) 0.14 0.41 0.73 0.73 0.76 0.75
(0.09, 0.21) (0.32, 0.51) (0.64, 0.82) (0.67, 0.79) (0.72, 0.80) (0.72, 0.78)
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alternative to benzodiazepines. Safety concerns in non-
benzodiazepine hypnotics have been noted with elevated
hazards of dying compared to those prescribed no hyp-
notics.19 It is imperative that if these patterns reflect an
attempt to assist with sleep symptom management that
different treatment approaches be considered that include
cognitive behavioral therapy for insomnia (CBT-I) and safer
medication options.
Table 4. Impact of Adjustment for Demographic Characteristics and Psychiatric Comorbidity on Gender-Based Differences in Prescribing,
Multivariable Logistic Regression, FY09
Model SSRI/SNRI Benzodiazepine Atypical antipsychotics
OR (95 % CI)* c statistic OR (95 % CI) c statistic OR (95 % CI) c statistic
Unadjusted 1.37 0.511 1.47 0.514 1.31 0.510
(1.34, 1.40) (1.43, 1.50) (1.28, 1.35)
Demographics only 1.34 0.567 1.63 0.608 1.08 0.605
(1.31, 1.37) (1.60, 1.67) (1.05, 1.10)
Comorbidity only 1.13 0.630 1.27 0.590 1.25 0.607
(1.10, 1.15) (1.24, 1.30) (1.22, 1.28)
Demographics and comorbidity 1.15 0.658 1.47 0.653 1.08 0.652
(1.12, 1.18) (1.44, 1.51) (1.05, 1.11)
*Odds ratio and 95 % confidence interval for the likelihood of receiving medication in women compared to men
Table 3. Demographic Characteristics and Psychiatric Comorbidity as Independent Predictors of Prescribing, Multivariable Logistic
Regression, FY09
Diagnosis SSRI/SNRI Benzodiazepine Atypical antipsychotics
Women Men Women Men Women Men
OR (95 % CI) OR (95 % CI) OR (95 % CI) OR (95 % CI) OR (95 % CI) OR (95 % CI)
Demographics
Age group, years
<30 0.80 0.85 0.59 0.78 0.58 0.66
(0.75, 0.86) (0.82, 0.87) (0.55, 0.64) (0.75, 0.80) (0.54, 0.63) (0.64, 0.69)
30–39 0.96 1.01 0.78 0.93 0.81 0.89
(0.89, 1.02) (0.98, 1.04) (0.73, 0.83) (0.90, 0.96) (0.75, 0.87) (0.86, 0.92)
40–49 Reference Reference Reference Reference Reference Reference
50–64 1.02 0.96 1.01 1.00 0.85 0.87
(0.96, 1.09) (0.93, 0.99) (0.95, 1.07) (0.96, 1.03) (0.79, 0.90) (0.84, 0.90)
≥65 0.88 0.85 0.84 0.86 0.36 0.59
(0.72, 1.06) (0.81, 0.88) (0.70, 1.01) (0.83, 0.90) (0.28, 0.47) (0.57, 0.62)
Urban residence 0.90 0.88 0.90 0.86 0.94 0.95
(0.85, 0.95) (0.86, 0.89) (0.85, 0.95) (0.84, 0.87) (0.88, 0.99) (0.94, 0.97)
Service connection >50 % 1.26 1.29 1.47 1.46 1.28 1.19
(1.20, 1.32) (1.27, 1.31) (1.40, 1.54) (1.43, 1.48) (1.22, 1.35) (1.17, 1.21)
Service era
Pre-Vietnam 0.70 0.80 0.92 1.07 0.98 0.80
(0.54, 0.92) (0.77, 0.82) (0.71, 1.20) (1.03, 1.11) (0.68, 1.42) (0.77, 0.84)
Vietnam Reference Reference Reference Reference Reference Reference
Post-Vietnam 0.89 1.00 0.82 0.92 0.96 1.32
(0.82, 0.97) (0.98, 1.03) (0.76, 0.89) (0.90, 0.95) (0.88, 1.04) (1.28, 1.36)
PTSD dx duration in VA
New diagnosis 0.76 0.69 0.63 0.53 0.58 0.47
(0.71, 0.80) (0.68, 0.70) (0.59, 0.67) (0.52, 0.54) (0.54, 0.62) (0.46, 0.48)
1–2 years 1.06 0.98 0.80 0.73 0.84 0.70
(1.00, 1.13) (0.96, 0.99) (0.76, 0.85) (0.72, 0.74) (0.79, 0.89) (0.69, 0.72)
3+ years Reference Reference Reference Reference Reference Reference
Comorbidity
Depressive disorder 2.88 2.61 1.36 1.41 1.04 1.43
(2.75, 3.01) (2.58, 2.64) (1.30, 1.42) (1.39, 1.43) (0.99, 1.10) (1.41, 1.45)
Panic disorder 1.72 1.71 3.48 4.51 1.31 1.55
(1.57, 1.89) (1.65, 1.77) (3.21, 3.78) (4.36, 4.67) (1.21, 1.42) (1.50, 1.61)
GAD 1.31 1.41 1.92 2.46 1.12 1.30
(1.19, 1.45) (1.36, 1.46) (1.75, 2.10) (2.38, 2.54) (1.02, 1.24) (1.26, 1.35)
OCD 1.65 1.88 1.53 1.62 2.14 2.29
(1.37, 1.99) (1.72, 2.05) (1.30, 1.80) (1.50, 1.74) (1.82, 2.51) (2.12, 2.46)
Social phobia 1.44 1.61 1.30 1.58 1.20 1.34
(0.97, 2.13) (1.40, 1.84) (0.93, 1.81) (1.40, 1.78) (0.85, 1.70) (1.19, 1.52)
Substance use disorder 1.29 1.10 1.11 0.92 2.71 1.92
(1.22, 1.37) (1.08, 1.11) (1.05, 1.18) (0.90, 0.93) (2.56, 2.87) (1.89, 1.95)
Traumatic brain injury 1.00 1.16 1.23 1.32 1.14 1.21
(0.88, 1.13) (1.12, 1.20) (1.09, 1.39) (1.27, 1.36) (1.00, 1.30) (1.17, 1.25)
Each column is a separate multiple logistic regression model
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This study has several limitations. The use of adminis-
trative data allows us to describe prescribing trends among
veterans with PTSD and to determine predictors of
prescribing but does not allow us to fully determine the
justifications for the prescribed medications. While we were
able to determine rates of comorbid disorders using
administrative data, it is difficult to confirm their accuracy,
and there are other co-occurring disorders that may be
relevant that were not captured. Nor can we confirm the
timing (e.g., current active problem as in the case of a co-
occurring SUD or distant history) or severity of the co-
occurring disorders examined. It is also possible that there
may be gender-specific coding biases.
This work highlights important findings regarding gender
and PTSD that speak to the need for additional work in
several areas. We found differences between men and women
that are not explained by comorbidities, especially in the area
of prescribing of benzodiazepines. It is encouraging to see
prescriptions written for first-line pharmacotherapy treat-
ments for women with PTSD. Reduced benzodiazepine
findings in men are also encouraging, but we are left with
more questions than we have answers regarding the increased
prescribing frequency of benzodiazepines in women. It is still
possible that the observed gender differences in prescribing
are for what might be considered “appropriate reasons” that
take into account other co-occurring disorders or that they
reflect a greater willingness among women toward taking
medications for mental health problems rather than decision
making among prescribers. It is also possible the complexity
of these patients may cause clinicians to respond to treatment
failures by indiscriminately trying different medications. VA
has an opportunity to develop policies and interventions that
will improve the care that women veterans returning from
war receive for PTSD and decrease the heavy burden of
greater comorbid mental health disorders, particularly in the
treatment of SUD and TBI. Provider education is sorely
needed for this primarily reproductive-aged cohort to inform
clinicians about gender differences in side effects, medication
dosing and particularly about sex differences in pharmaco-
kinetics of psychotropic medications in order to provide
access to quality PTSD care for our veteran women.
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